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BACKGROUND. Breast cancers that are negative for estrogen receptor (ER), proges-
terone receptor (PR), and human epidermal growth factor receptor 2 (HER2)
(triple negative [TN]) have been associated with high-grade histology, aggressive
clinical behavior, and poor survival. It has been determined that breast cancers
that are negative for ER and PR but positive for HER2 (double negative [DN])
share features with TN breast cancers. In this report, the authors quantified the
contribution of HER2 as well as demographic and tumor characteristics to the
survival of women with TN tumors, DN tumors, and other breast cancers (OBC).
METHODS. In total, 61,309 women who were diagnosed with invasive breast can-
cer between 1999–2004 were identified in the California Cancer Registry. Demo-
graphic and tumor characteristics of women with TN tumors were compared
with those from women with DN tumors and women with OBC. A compound
proportional hazards regression analysis (PHPH) (a generalization of the Cox pro-
portional hazards model) was used to model these characteristics.
RESULTS. Women with TN tumors were younger, African American, Hispanic,
and of lower socioeconomic status (SES), whereas women with DN tumors were
slightly older; African American, and Asian/Pacific Islander. Women with TN and
DN tumors presented with larger, higher grade, and higher stage than women
with OBC. Survival among women with TN tumors was poorer compared with
that among women with OBC but was nearly the same as that of women with
DN tumors. Results of the regression analysis indicated that disease stage, tumor
grade, SES, and race/ethnicity were significant risk factors for survival. Negative
ER and PR status was associated with an increased risk of death. There was a
small but significant difference in both long-term and short-term survival
patients who had TN tumors compared with patients who had DN tumors.
CONCLUSIONS. Patients with TN tumors shared many clinical, demographic, and
tumor features and had survival that was very similar survival to that of patients
with DN tumors, and survival for both groups contrasted greatly with survival for
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patients with OBC. Disease stage, tumor grade, SES, race/ethnicity, negative ER
and PR status, rather than negative HER2 status, were risk factors for survival.
Cancer 2008;112:737–47.  2008 American Cancer Society.
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B reast cancer is the most common cancer amongwomen in California. Despite decreased mortal-
ity, breast cancer remains a significant cause of can-
cer death.1 Breast cancer incidence and mortality
vary greatly according to demographic factors, such
as age, race/ethnicity, and socioeconomic status
(SES).2–4 These demographic factors produce wide
disparities in survival, including lower rates for
younger women,5–9 ethnic minority women,10,11 and
less affluent women.12,13 Breast cancer survival
depends on prognostic factors like tumor size, histo-
logic grade, and tumor receptor status, regardless of
treatment.14 These prognostic factors are distributed
differentially in the population by age and race/eth-
nicity.15–19
Human epidermal growth factor (HER), estrogen,
and progesterone regulate cell growth, apoptosis,
and differentiation. Tumor cell expression for recep-
tors of HER2 is considered a prognostic factor in
breast cancer19–21 and is one of the risk-stratification
features of the St. Gallen International Consensus
Guidelines.22 Overexpression of HER2 is associated
with worse clinical outcomes in both patients with
lymph node-negative cancer and patients with lymph
node-positive cancer.23,24 These patients tend to have
more aggressive disease, which leads to shortened
overall survival.25 However, it has not been demon-
strated that HER2-negative tumors predict a poor
prognosis in women with breast cancer in the ab-
sence of other tumor marker data.26 Endocrine sensi-
tivity, as assessed by the expression of estrogen
receptor (ER) and/or progesterone receptor (PR), is
an important prognostic and predictive factor.
Patients who are negative for these receptors have a
worse prognosis, at least in the first 5 to 10 years af-
ter treatment.27,28 However, these tumor markers are
invaluable as predictors of response to therapy: ER
and PR predict response to endocrine therapy,27 such
as tamoxifen, aromatase inhibitors, and ovarian sup-
pression; and HER2 overexpression predicts for
response to targeted anti-HER2 therapy.29,30
Breast cancer is a heterogeneous disease with a
wide spectrum of clinical, pathologic, and molecular
features.31–33 Gene-expression profiling studies have
identified at least 4 categories of breast cancer.31,33
These molecular categories correlate with biomarker
phenotypes (luminal A is ER-positive and/or PR-posi-
tive/HER2-negative, luminal B is ER-positive and/or
PR-positive/HER2-positive, HER2 overexpression is
ER-negative/PR-negative/HER2-positive, and basal-
like is ER-negative/PR-negative/HER2 negative)33,34
and have distinct differences in disease progression,
prognosis, and survival.33 Specifically, the basal-like
subtype, known as triple-negative (TN), is associated
with aggressive histology, poor clinical outcomes,33,35
and BRCA1-related breast cancer.36,37 TN breast can-
cer is more prevalent among young, premenopausal,
African-American,33,38,39 and Hispanic women39 and
is a strong contributing factor to the poor clinical
outcomes in these women.
In an earlier investigation, we observed that
patients with ER-negative/PR-negative/HER2-nega-
tive (TN) breast tumors or TN breast cancers had
demographic, clinical/pathologic features, and sur-
vival that were similar to those of patients with
ER-negative/PR-negative/HER2-positive breast can-
cers, that is, the HER2-overexpressed molecular sub-
type or double negative [DN].40 We observed that
overall survival was nearly identical for women with
the TN and DN phenotypes, suggesting that HER2
played a minimal role in survival. The current study
extends our earlier observations by quantifying the
contribution of HER2, along with clinical, demo-
graphic, and other tumor characteristics, to the
survival of women with TN and DN tumors and of
women with other breast cancers (OBC).
MATERIALS AND METHODS
Patient Identification
Patients who were included in the current analyses
were identified by using the California Cancer Regis-
try (CCR), a population-based registry composed of 8
regional registries that collect cancer incidence and
mortality data for the entire population of California.
In 1985, California state law mandated the reporting
of all newly diagnosed cancers in California, and sta-
tewide implementation began January 1, 1988. Cases
are reported to the Cancer Surveillance Branch of the
California Department of Health Services from hospi-
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tals and any other facilities that provide care or ther-
apy to cancer patients who reside in California.41 For
this study, women with primary, invasive breast can-
cer (International Classification of Diseases for Oncol-
ogy, 3rd edition [ICDO-3] sites C50.0-C50.9)42 who
were diagnosed between January 1, 1999 and Decem-
ber 31, 2004 and were reported to the CCR as of Oc-
tober 2006 were included.
The CCR requires the collection of tumor marker
information from the medical record on the ER and
PR status of breast cancers diagnosed on or after Jan-
uary 1, 1990 and requires data on the HER2 status of
breast cancers diagnosed on or after January 1,
1999.41 Issues associated with the collection and re-
cording of hormone receptor data have been
described elsewhere.43 ER and PR status are recorded
according to the pathologist’s interpretation of the
assays. ER and PR are considered negative if immu-
noperoxidase staining of tumor cell nuclei is <5%.
ER and PR status also may be determined by exam-
ining cytosol protein. ER is considered negative if
there is <3 fmol/mg of cytosol protein, and PR is
considered negative if there is <5 fmol/mg of cytosol
protein.44 HER2 is assessed through immunohisto-
chemistry (IHC) or fluorescence in situ hybridization
(FISH). IHC is scored on a qualitative scale from 0 to
31, based on interpretation of staining intensity,
with 0 and 11 classified as negative, 21 classified as
borderline, and 31 classified as positive.45 FISH is
scored on a quantitative scale with <2 copies of the
HER2 gene classified as negative and with 2 copies
classified as positive.46
Patients were categorized into distinct groups
based on their tumor marker status. Patients who
had tumors that were negative for ER, PR, and HER2
were referred to as TN, patients who had tumors that
were classified as negative for ER and PR but positive
for HER2 were referred to as DN, and patients who
had tumors that were classified as neither TN nor
DN were referred to as OBC. Patients who had at
least 1 unknown tumor marker and those with bor-
derline results were excluded from these analyses.
Variables
Race/ethnicity was classified into 4 mutually exclu-
sive categories of Asian-Pacific Islander (API), His-
panic, non-Hispanic black, and non-Hispanic white.
Race/ethnicity was based on information obtained
from the medical record, which can be derived from
patient self-identification, assumptions based on per-
sonal appearance, or inferences based on the race/
ethnicity of the parents, birthplace, surname, or
maiden name. Hispanic ethnicity was based on in-
formation from the medical record and computer-
ized comparisons to the 1980 United States Census
List of Hispanic Surnames. Patients who were identi-
fied as Hispanic on the medical record or patients
who were identified as white, black, or of unknown
race with a Hispanic surname were classified as His-
panic.47 Patients with unknown race/ethnicity, age,
or sex were excluded from these analyses.
SES was assigned based on patient’s census block
group (2000 United States Census) derived from their
address at the time of initial diagnosis as reported in
the medical record. This SES variable is an index that
uses education, employment characteristics, median
household income, proportion of the population liv-
ing 200% below the Federal Poverty Level, median
rent, and median housing value of census tract of
residence for case and denominator population. A
principal components analysis was used to identify
quintiles of SES ranging from 1 (the lowest) to 5 (the
highest).48
Stage at diagnosis was collected from the
patient’s medical record and was coded according to
the American Joint Commission on Cancer (AJCC)
Cancer Staging Manual, 6th edition.49 The CCR col-
lected Surveillance, Epidemiology, and End Results
(SEER) Extent of Disease (EOD) data for breast can-
cer cases diagnosed from 1988 through December
200350 and, in 2004, began collecting Collaborative
Staging data items.51 EOD was converted to AJCC
stage at diagnosis by using SEER guidelines.52 For
some of these analyses, stages III and IV at diagnosis
were combined, and patients who had unknown dis-
ease stage at diagnosis were omitted. Tumor grade
was collected from the medical record and was
coded according to ICDO-3.42
Statistical Analysis
Statistical significance for pairwise comparisons was
determined by using the Wilcoxon signed-rank test (to
compare medians) and the test for independent pro-
portions.53 Comparisons of survival among patients’
tumor marker phenotypic groups and stage at diagno-
sis were performed by using the 5-year cumulative
relative survival of all available years of data. Counts,
5-year cumulative relative survival, and 95% confi-
dence intervals (95% CIs) were calculated by using
SEER*Stat software (version 6.2.4; Silver Spring, Md).
Because previous studies indicated that the pro-
portional hazards (PH) model is positioned poorly to
reproduce the effects of ER and PR status on breast
cancer survival, a more general survival model was
selected for the current analysis.54 Survival was mod-
eled using a compound regression analysis method
(PHPH) regression model, a generalization of the Cox
PH model that was developed for use when data
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indicate a possibility of long-term survival and non-
proportional hazards. Departures from the propor-
tionality assumption indicate that hazard ratios
(HRs) vary with time and are introduced in the form
of short-term effects.55 A pure short-term effect cor-
responds to survival curves that converge with time
and long-term survivors who have no differences
with respect to variables included in the model. The
PHPH model is constructed by a composition of 2
separate PH models: long-term hazard and short-
term hazard. Both models are defined by using limit-
ing behavior of survival and hazard functions; hence,
there is no sharp cutoff point between short-term
and long-term survival. The PHPH model55 describes
the survival function S(t|z) as follows:
ðStjzÞ ¼ expfuðzÞ½1 FðtÞhðzÞg; ð1Þ
where F(t) is a baseline survival function (‘‘proper’’
means 1 with zero chance of long-term survival), and
y(z) and h(z) are predictors that depend on the vari-
ables of interest z (covariates). In the equation above,
h(z) describes the short-term survival effects. Thus
y(z)/y(0) and h(z) represent the relative risks (RR) for
long- and short-term survival, respectively. The diver-
sity of responses reproduced by the PHPH model
includes crossing survival curves characterized by
counteracting short-term and long-term effects. A
universal estimation algorithm, the so-called quasi-
EM procedure, has been developed to provide infer-
ence for such models.56 It should be stressed that
‘‘long-term’’ survival in the semiparametric model1 is
a mathematical term used to define risks operating
at the end of the follow-up range. The follow-up
range in the current study is 6 years, which, by the
standards of breast cancer, cannot be identified with
the time when the risk becomes negligible, because
many 6-year survivors still are expected to fail.
RESULTS
We identified 110,163 incident cases of invasive
breast cancer from 1999 to 2004 from the CCR. Of
these selected cases, 61,309 had definitive results for
all 3 tumor markers on record. A comparison of the
cases that were included in these analyses with cases
that were omitted has been discussed elsewhere. We
observed no significant differences in results when
omitted cases were added to the analyses.39
Table 1 compares the demographic and tumor
characteristics of TN patients with both OBC patients
and DN patients. The median age at diagnosis of
patients with TN tumors was significantly younger
than the median age of OBC patients (54 years vs 60
years; P  .001). Patients with TN tumors were signif-
icantly more likely to reside in areas of lower SES
than OBC patients (P < .001). A significantly higher
proportion of non-Hispanic black and Hispanic
patients had tumors that were TN (P  .001 for
both). TN tumors were significantly more likely to be
larger (P  .001), poorly differentiated (P  .001), or
anaplastic (P  .01), and they were significantly more
likely to present as stage II or III disease (P  .001
and P  .01, respectively).
Patients with DN tumors and patients with TN
tumors were very similar and had few differences
that reached statistical significance. The median age
of patients with DN tumors was only slightly older
than the median age of patients with TN tumors.
There were no significant differences in SES between
these 2 groups. Race/ethnicity was distributed simi-
larly, with the exception of API women, who were
significantly more likely to have DN tumors (P  .05).
Both DN tumors and TN tumors tended to be
approximately the same size and tended to be poorly
differentiated at diagnosis, and significantly fewer
DN tumors presented as grade 3 (P  .001). Although
the distribution by stage of diagnosis was similar for
DN tumors and TN tumors, a significantly larger pro-
portion of patients with DN tumors presented with
stage III disease (P  .01).
The 5-year cumulative relative survival rates by
tumor maker status were 76.2% (95% CI, 74.4–78%)
for women with TN tumors, 75.9% (95% CI, 73.6–
78.3%) for women with DN tumors, and 94.2% (95%
CI, 93.6–94.8%) for women with OBC (data not
shown). Figure 1 illustrates 5-year cumulative relative
survival by tumor marker status and by stage. Rela-
tive survival patterns of patients with TN tumors and
patients with DN tumors appeared to be similar, and
both were in sharp contrast to the survival patterns
in patients with OBC. Overall, relative survival among
women with TN tumors generally was poorer than
that for women with OBC but was nearly the same
as that for women with DN tumors. Among patients
with stage I disease, the relative survival of patients
with TN tumors was significantly shorter than that
for patients with OBC (P 5 .0032) but did not differ
significantly from that of DN patients. Among
patients with stage II and III/IV disease, the relative
survival of patients with TN tumors was significantly
shorter than the relative survival both for patients
with OBC (P < .001 for both) and for patients with
DN tumors (P 5 .01 and P < 0.001, respectively).
The relative contribution of demographic and tu-
mor characteristics were modeled by using PHPH
regression (Table 2). In the PHPH models, breast
cancer survival data were fit with disease stage; tu-
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mor grade; ER, PR, and HER2 status; SES; and race/
ethnicity as explanatory variables for both long-term
and short-term probability of death while controlling
for age at diagnosis. In the full model, not surpris-
ingly, the long-term probability of death increased
significantly with progressive stage at diagnosis and
tumor histology (P < .0001). High SES was associated
with better long-term survival. For SES level 3 versus
1, the long-term difference was characterized by an
RR of 0.82 (P 5 .038); and, for SES level 5 versus 1,
the difference was characterized by an RR of 0.75
(P 5 .003). Similar effects were observed for short-
term survival, although only SES level 5 versus 1
demonstrated a significant difference (HR, 0.8;
P 5 .003).
Non-Hispanic black women had worse survival
compared with non-Hispanic white women (long-
term RR, 1.32; P 5 .0005). The effect of race followed
the PH assumption, indicating no short-term depar-
tures (P 5 .865). Although that may be meaningful to
patient survival, differences in many of demographic
and tumor characteristics were not statistically signif-
icant for short-term survival. The exception was dis-
ease stage at diagnosis, which maintained a pattern
similar to that observed in long-term survival but
with a reduced effect. Most important, negative re-
ceptor status for each of the tumor markers (ER, PR,
and HER2) was associated with an adverse effect on
both long- and short-term survival with the excep-
tion of long-term survival on HER2 (RR, 0.98;
P 5 .715). Negative ER status (RR, 1.48; P < .0001)
and negative PR status (RR, 1.20; P 5 .030) were asso-
ciated with an increase in the long-term risk of
death, whereas short-term effects were even stronger
TABLE 1






PNo. % No. % No. %
Total no of patients 48,851 100 8022 100 4436 100
Median age at diagnosis, y 60 54 .001 55
Age group at diagnosis, y
49 11,735 24 2870 35.8 .001 1474 33.2
>50 37,116 76 5152 64.2 .001 2962 66.8 .05
SES
1 (Low) 4651 9.5 1077 13.4 .001 596 13.4
2 7388 15.1 1470 18.3 .01 832 18.8
3 9874 20.2 1687 21 933 21
4 12,059 24.7 1866 23.3 985 22.2
5 (High) 14,879 30.5 1922 24 .001 1090 24.6
Race/ethnicity
Non-Hispanic white 35,776 73.2 4922 61.4 .001 2700 60.9
Non-Hispanic black 2094 4.3 860 10.7 .001 318 7.2 .05
Hispanic 6219 12.7 1493 18.6 .001 830 18.7
Asian-Pacific Islander 4447 9.1 690 8.6 563 12.7 .05
Other/unknown 315 0.6 57 0.7 25 0.6
Median tumor size, mm 16 22 .001 23 .05
Histologic grade
1 12,180 24.9 238 3 .001 91 2.1
2 21,550 44.1 1267 15.8 .001 866 19.5 .05
3 11,081 22.7 5744 71.6 .001 3003 67.7 .001
4 672 1.4 390 4.9 .01 207 4.7
Unknown 3368 6.9 383 4.8 269 6.1
AJCC stage at diagnosis
I 23,133 47.4 2599 32.4 .001 1234 27.8 .01
II 18,835 38.6 3827 47.7 .001 1946 43.9 .01
III 3452 7.1 942 11.7 .001 751 16.9 .01
IV 1468 3 333 4.2 279 6.3
Other/unknown 1963 4 321 4 226 5.1
OBC indicates other breast cancers; DN, double negative (estrogen receptor [ER] negative, progesterone receptor [PR] negative, and HER2 positive); TN, triple
negative (ER negative, PR negative, and HER2 negative); SES, socioeconomic status; AJCC, American Joint Committee on Cancer.
Red lines present a comparison of TN and OBC. Blue lines present a comparison of TN and DN.
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(ER-negative tumors: RR, 1.70; P < .0001; PR-negative
tumors: RR, 1.41; P 5 .001). Negative HER2 status
had little effect on long-term survival (RR, 0.98;
P 5 .715) but increased the short-term risk of death
(RR, 1.18; P 5 .038).
Next, the phenotypic combinations TN and DN
were used as explanatory variables in the full model
rather than individual tumor makers, whereas all
other variables remained the same. In this model,
nearly identical patterns were observed in both long-
term and short-term survival for stage at diagnosis,
tumor histology, race/ethnicity, and SES, similar to
what was observed in the first model. Patients with
TN tumors and patients with DN tumors had a clear
survival disadvantage in long-term and short-term
survival compared with patients who had OBC.
Patients who had TN tumors showed 1.74 times
higher long-term risk (P < .0001) compared with
patients who had OBC; whereas the short-term risk
had a greater effect (HR, 2.27; P < .0001). Patients
who had DN tumors had 1.48 times higher long-term
risk compared with patients who had OBC (P < .0001)
and had an HR of 1.78 (P < .0001) for the short-term
effect compared with patients who had OBC. TN
tumors were compared with DN tumors in the full
model, which was rerun with a different coding for
the phenotype variable (all other variables remained
the same; DN was the assumed baseline category
of the phenotype variable). There was a small but
significant difference in both long-term survival (HR,
1.17) and short-term survival (HR, 1.29) for patients
who had TN tumors compared with patients who
had DN tumors.
DISCUSSION
In this large, population-based cohort study, we
described the demographic, clinical, and tumor char-
FIGURE 1. Five-year relative cumulative survival for invasive female breast cancers by tumor marker phenotype and American Joint Committee on Cancer
stage at diagnosis: California, 1999–2004. Double negative (DN) indicates tumors that were estrogen receptor (ER) negative, progesterone receptor (PR) nega-
tive, and human epidermal growth factor receptor 2 (HER2) positive; triple negative (TN), tumors that were ER negative, PR negative, and HER2 negative.
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TABLE 2
Compound Proportional Hazards (Long-term Hazard and Short-term Hazard) Regression Analysis of Survival
by Selected Tumor and Demographic Characteristics in Women With Invasive Breast Cancer, California,
1999 to 2004
Characteristic
Model 1 Model 2
HR 95% CI P HR 95% CI P
Long-term risk
Stage at diagnosis
Regional vs localized 3.27 2.83–3.78 <.0001 3.31 2.86–3.83 <.0001
Distant vs localized 14.90 12.50–17.76 <.0001 15.73 13.17–18.78 <.0001
Tumor histology (differentiation)
Moderate vs well 1.97 1.42–2.73 <.0001 1.92 1.39–2.66 <.0001
Poor vs well 3.69 2.68–5.06 <.0001 3.76 2.74–5.16 <.0001
Undifferentiated vs well 3.45 2.36–5.05 <.0001 3.39 2.32–4.94 <.0001
SES
2 vs 1 (Low) 1.03 0.85–1.25 .745 1.03 0.85–1.24 .789
3 vs 1 (Low) 0.82 0.68–0.99 .038 0.82 0.68–0.98 .031
4 vs 1 (Low) 0.86 0.71–1.05 .132 0.88 0.72–1.07 .214
5 vs 1 (Low) 0.75 0.62–0.91 .003 0.75 0.62–0.91 .004
Race/ethnicity
NH black vs NH white 1.32 1.09–1.60 .005 1.32 1.09–1.61 .005
Hispanic vs NH white 0.95 0.76–1.18 .630 0.97 0.77–1.21 .767
API vs NH white 1.11 0.94–1.30 .216 1.10 0.93–1.29 .265
Tumor receptor status
ER negative vs positive 1.48 1.26–1.73 <.0001
PR negative vs positive 1.20 1.02–1.41 .030
HER2 negative vs positive 0.98 0.87–1.10 .715
Phenotype
DN vs OBC 1.48 1.26–1.73 <.0001
TN vs OBC 1.74 1.52–2.00 <.0001
TN vs DN 1.17 1.00–1.37 .045
Short-term risk
Stage at diagnosis
Regional vs localized 1.31 1.08–1.58 .006 1.29 1.07–1.56 .009
Distant vs localized 3.04 2.41–3.83 <.0001 2.89 2.28–3.65 <.0001
Tumor histology (differentiation)
Moderate vs well 0.98 0.65–1.49 .928 1.05 0.69–1.59 .819
Poor vs well 1.08 0.72–1.61 .709 1.16 0.78–1.71 .476
Undifferentiated vs well 1.28 0.78–2.08 .332 1.45 0.89–2.34 .132
SES
2 vs 1 (Low) 0.97 0.76–1.25 .830 0.97 0.75–1.25 .812
3 vs 1 (Low) 1.06 0.83–1.35 .641 1.09 0.85–1.38 .507
4 vs 1 (Low) 0.82 0.64–1.06 .134 0.79 0.61–1.03 0.078
5 vs 1 (Low) 0.80 0.62–1.03 .087 0.80 0.62–1.03 .080
Race/ethnicity
NH black vs NH white 0.98 0.76–1.26 .865 0.98 0.75–1.26 .846
Hispanic vs NH white 0.83 0.62–1.11 .219 0.82 0.61–1.10 .178
API vs NH white 0.87 0.71–1.08 .207 0.89 0.72–1.10 .272
Tumor receptor status
ER negative vs positive 1.70 1.38–2.08 <.0001
PR negative vs positive 1.41 1.14–1.73 .001
HER2 negative vs positive 1.18 1.01–1.38 .038
Phenotype
DN vs OBC 1.78 1.45–2.19 <.0001
TN vs OBC 2.27 1.90–2.72 <.0001
TN vs DN 1.29 1.04–1.58 .018
Log (-log) of baseline probability
of long-term survival* 0.04 <.0001 0.03 0.02–0.04 <.0001
HR indicates hazard ratio; 95% CI, 95% confidence interval; SES, socioeconomic status; NH, non-Hispanic; API, Asian-Pacific Islander; ER, estrogen receptor;
PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative (ER negative, PR negative, and HER2 negative); DN, double
negative (ER negative, PR negative, and HER2 positive).
* For all variables combined (stage at diagnosis, histology, SES, race/ethnicity, receptor status, and phenotype), the log (-log) of baseline probability of long-
term survival was 0.03; for all subgroups combined, the log (-log) of baseline probability of long-term survival was 0.02.
acteristics of patients with invasive breast cancer in
California who had either TN tumors or DN tumors
and compared them with all other invasive breast
cancer phenotypes. We observed that patients who
had TN tumors and patients who had DN tumors
shared many clinical, demographic, and tumor fea-
tures; had very similar survival; and contrasted
greatly with women who had OBC.
In agreement with other studies, we demon-
strated that important risk factors for the women
with TN tumors were younger age, race/ethnicity
(significant differences for non-Hispanic black and
Hispanic women), and lower SES.33,38,39 Women with
TN breast cancers were diagnosed with larger
tumors, more aggressive histology, and at a more
advanced stage,33,39 which contributes to faster pro-
gression to metastasis and poorer prognosis.57–59
Risk factors for DN tumors and TN tumors were
slightly older age and race/ethnicity (significant dif-
ferences for non-Hispanic black and API); however, it
is noteworthy that SES played no role. Women with
DN and breast cancer presented with larger tumors,
more aggressive histology, and more advanced dis-
ease stage.
Patients with TN tumors and patients with DN
tumors had very similar survival that was signifi-
cantly shorter than the survival of patients who had
OBC regardless of disease stage at diagnosis.33,39
Modeling data for individual tumor markers sug-
gested that the shortened survival of women with TN
tumors and women with DN tumors was caused pri-
marily by the negative ER and PR status and that re-
ceptor negativity affected long-term survival more
than short-term survival. The statistically insignifi-
cant contribution of HER2 to the lethality of these
phenotypes requires further study.
Poor outcomes in women with breast cancer
have been associated with negative ER and PR status
without regard to HER2 status.28,60 Some investiga-
tors have postulated that all ER-negative tumors
carry a relatively poor prognosis, irrespective of the
cytokeratin composition or the gene expression sig-
nature.26 Tumors that are HER2 positive have been
associated for some time with worse clinical out-
comes.24,61 The survival of women with TN tumors is
almost identical to the survival of women with DN
tumors, as reported previously.26,32,33,62,63 Jumppanen
et al. concluded that, within the ER-negative tumor
entity, there was no difference in survival between
nonbasal tumors and basal-like tumors as classified
by IHC or gene expression.26 Previous studies were
focused principally on defining gene expression-
based classification of breast cancers32,62,63 or specif-
ically on characterizing the basal-like phenotype
among young African-American women,33 and they
did not discuss the relative importance of HER2, per-
haps because small sample sizes may have precluded
further investigation.
In the current study, patients who had TN
tumors had a small but significantly increased risk
for long-term and short-term earlier death compared
with patients who had DN tumors. We observed that
African-American women consistently were at signifi-
cantly greater risk of death than women of other eth-
nicities. Bivariate analyses indicated that Hispanic
women were at greater risk of having TN tumors,
and API women were at greater risk of having DN
tumors. Unlike African-American ethnicity, Hispanic
and API ethnicity were not identified as independent
contributors to early death in multivariate analyses.
Although SES was prominent in the bivariate analysis
for patients with TN tumors, it played a limited role
in short-term survival; however, it had significant
long-term survival effects in multivariate analyses.
Racial, ethnic, and SES disparities in breast can-
cer incidence and mortality are well documented in
the medical literature. Numerous studies have
demonstrated that African-American women have a
lower incidence of breast cancer but worse survival
compared with non-Hispanic white women.2,60,64–67
Fewer studies have described the risk for Hispanic
women, but those studies indicated that, similar to
African-American women, Hispanic women had
lower incidence but worse survival.10,68,69 It is
believed that breast cancer survival among African-
American and Hispanic women is compromised, in
that these women are younger at the time of diagno-
sis,5,70–72 their tumors more often are ER-nega-
tive,64,71,73 and they present at higher stages,74
perhaps because of issues associated with access to
healthcare.12,75–78 In studies that adjusted for clinical
and SES factors, African-American women continued
to have slightly but significantly poorer survival com-
pared with white women, whereas the differences in
survival among Hispanic and Asian women com-
pared with white women were ameliorated.79–81
The current study included a large number of
patients from an ethnically diverse population, thus
allowing us to compare the clinical, demographic,
and tumor features of women with TN breast cancer,
DN breast cancer, and OBC. Nevertheless, this study
was not without limitations. The data were taken
from a population-based cancer registry and were
not supplemented with other clinical data or gene-
expression analyses. Population-based cancer registry
data derive from many sources. Histologic grading of
tumors and tests for ER, PR, and HER2 were per-
formed by a wide variety of laboratories without cen-
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tral review. In addition, almost 50% of the initial
study population lacked information about ER, PR,
and HER2 status, with the latter constituting the bulk
of missing data. In 1999, the CCR began collection of
HER2 results; however, >50% of newly diagnosed
breast cancers lacked this test result. By 2003, HER2
testing of primary breast cancer was more common,
and >70% of patients with breast cancer included
HER2 data.43 HER2 testing was not recommended
for all women with invasive breast cancer until
200782; thus an increase in testing and improvements
in documentation over time are expected. Finally, ad-
juvant therapy information in the CCR was consid-
ered limited, so we did not include it in the survival
models. Therefore, we made no attempt to attribute
overall survival to any specific form of therapy. The
omission of therapies may confound the correlation
between overall breast cancer survival and pheno-
typic group.
In summary, the current results indicate that
patients with TN tumors share many clinical, demo-
graphic, and tumor features and have survival that is
almost identical to that of patients with DN tumors.
We also observed that disease stage, tumor grade,
SES, race/ethnicity, and negative ER and PR status
remained as significant and independent risk factors
for long-term survival. In addition, we demonstrated
that negative ER and PR status, rather than negative
HER2 status, was the predominant factor contribut-
ing to poor survival. The TN phenotype, although it
is a useful surrogate marker for the identification of
basal-like breast cancers, may not explain all of the
poor prognostic features of breast cancer in young
African-American women. The correlations between
race/ethnicity, SES, and breast cancer survival are
provocative and difficult to untangle, and this diffi-
culty underscores the need for more precise report-
ing of patient characteristics and tumor factors in
future studies.
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